Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Go back to Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases| (NASDAQ: DNTH) | Delayed: 97.50 -3.62 (3.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $101.12 | 52 Week High | $ | |||
| Open | $101.12 | 52 Week Low | $ | |||
| Day High | $104.55 | P/E | N/A | |||
| Day Low | $97.17 | EPS | $ | |||
| Volume | 356,950 | |||||
